U.S. Markets close in 5 hrs 43 mins
  • S&P 500

    4,123.20
    -5.60 (-0.14%)
     
  • Dow 30

    33,726.49
    -74.11 (-0.22%)
     
  • Nasdaq

    13,840.59
    -59.59 (-0.43%)
     
  • Russell 2000

    2,224.76
    -18.71 (-0.83%)
     
  • Crude Oil

    60.49
    +1.17 (+1.97%)
     
  • Gold

    1,731.90
    -12.90 (-0.74%)
     
  • Silver

    24.78
    -0.54 (-2.13%)
     
  • EUR/USD

    1.1918
    +0.0013 (+0.1073%)
     
  • 10-Yr Bond

    1.6760
    +0.0100 (+0.60%)
     
  • Vix

    17.62
    +0.93 (+5.57%)
     
  • GBP/USD

    1.3747
    +0.0041 (+0.2997%)
     
  • USD/JPY

    109.3590
    -0.2910 (-0.2654%)
     
  • BTC-USD

    60,190.91
    +479.45 (+0.80%)
     
  • CMC Crypto 200

    1,287.44
    -7.14 (-0.55%)
     
  • FTSE 100

    6,906.89
    -8.86 (-0.13%)
     
  • Nikkei 225

    29,538.73
    -229.33 (-0.77%)
     

Lawsuits Filed Against ICPT, HPQ and LRN - Jakubowitz Law Pursues Shareholders Claims

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / January 4, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

CONTACT JAKUBOWITZ ABOUT ICPT:
https://claimyourloss.com/securities/intercept-pharmaceuticals-inc-loss-submission-form/?id=11911&from=1

Class Period : September 28, 2019 - October 7, 2020

Lead Plaintiff Deadline : January 4, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

HP Inc. (NYSE:HPQ)

CONTACT JAKUBOWITZ ABOUT HPQ:
https://claimyourloss.com/securities/hp-inc-loss-submission-form/?id=11911&from=1

Class Period : November 6, 2015 - June 21, 2016

Lead Plaintiff Deadline : January 4, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) HP's channel inventory management and sales practices resulted in the sale of supplies to customers that did not need or want the product in order to artificially increase revenues and profits; (b) HP's channel inventory management and sales practices resulted in the sale of supplies to customers outside of designated regions at unsustainable discounts in order to artificially increase revenues and profits; (c) HP's channel inventory management and sales practices resulted in the sale of supplies at steep discounts to customers to encourage those customers to sell the supplies further down the supply channel, out of HP's inventory management metrics; and (d) as a result of (a)-(c) above, defendants' statements about HP's business condition and prospects were materially false and misleading when made.

K12 Inc. (NYSE:LRN)

CONTACT JAKUBOWITZ ABOUT LRN:
https://claimyourloss.com/securities/k12inc-loss-submission-form/?id=11911&from=1

Class Period : April 27, 2020 - September 18, 2020

Lead Plaintiff Deadline : January 19, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) K12 lacked the technological capabilities, infrastructures, and expertise to support the increased demand for virtual and blended education necessitated by the global pandemic; (ii) K12 lacked adequate cyberattack protocols and protections to prevent the disabling of its computer system; (iii) K12 was unable provide the necessary levels of administrative support and training to teachers, students, and parents; and (iv) based on the foregoing, Defendants lacked a reasonable basis for their positive statements about the Company's business, operations, and prospects and/or lacked a reasonable basis and omitted facts.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law



View source version on accesswire.com:
https://www.accesswire.com/622966/Lawsuits-Filed-Against-ICPT-HPQ-and-LRN--Jakubowitz-Law-Pursues-Shareholders-Claims